ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SANA
DNA (35) ATTO (44) PRME (30) SLBT (45) ⌘ Pro Terminal →

Sana Biotechnology Inc. (SANA) — RQD Stock Rating Cockpit

$2.40 -6.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.37

Sana Biotechnology Inc. (SANA) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $769.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SANA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Sana Biotechnology Inc. (NASDAQ: SANA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.40 (-6.61% 1D, market cap $769.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SANA ranks #671 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SANA compare to DNA and ATTO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SANA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DNA (Ginkgo Bioworks Holdings Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $721.3M) and ATTO (Attovia Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $693.4M). Among the 5-stock peer group, SANA leads on earnings multiple (N/A) while SANA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SANA?
▼

Per SANA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770121), Sana Biotechnology Inc. generated $700.9M in revenue (-8.2% YoY), -$244.2M in net income, and -$144.8M in free cash flow against $416.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.37 (-1.38%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (5)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$6 Bull$2 Base$2 Bear
📬 FREE SANA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SANA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY SANA SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$2.41-2.1% Next Q
Q2 (-2Q)
38
Grade E$2.36+4.7% Next Q
Q3 (-1Q)
36
Grade E$2.47-2.8% Next Q
Current
33
Grade E$2.40-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SANA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SANA currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.99) and Max Pain ($2.52) forces dealer call-delta covering toward $5.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SANA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SANA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $2$2.40H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SANA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -17.78% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

8/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like SANA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SANA)

  • ✓Walkthrough of SANA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SANA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.62%📐 HORIZONTAL RANGE
2026-11-03O $2.72H $2.72L $2.40C $2.40VOL 2.08M
RES: $4.23SUP: $2.06SMA50: $2.99SMA200: $3.37
$4.36$3.78$3.20$2.62$2.04RES $4.23SUP $2.06$2.402026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SANA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SANA Butterfly Map → + Track SANA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SANA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SANA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SANA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SANA)

Health Care Rank #671 of 1015 ⚔️ DNA vs SANA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SANA vs. DNA, ATTO, PRME, SLBT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sana Biotechnology Inc. (SANA) ranks #671 by composite RQD confidence (33/100, grade E) and #386 by equity capitalization ($769.4M). Within this direct 5-issuer industry benchmark cohort, SANA leads on earnings valuation at N/A trailing P/E, while SANA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with SANA at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SANA ACTIVE
Sana Biotechnology Inc.
E 33/100 — — -35.0% -6.61% $769.4M Benchmark Subject
DNA
Ginkgo Bioworks Holdings Inc. (Class A)
D- 35/100 — — -35.0% -12.13% $721.3M /dna-vs-sana →
ATTO
Attovia Therapeutics Inc.
D 44/100 — — — -0.92% $693.4M /atto-vs-sana →
PRME
Prime Medicine Inc.
E 30/100 — — -35.0% -5.93% $856.1M /prme-vs-sana →
SLBT
SL Science Holding Limited
D 45/100 — — — +5.83% $672.9M /slbt-vs-sana →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770121 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sana Biotechnology Inc. (SANA) reported GAAP revenue of $700.9M (-8.2% vs. FY2024 revenue of $763.6M , and -14.6% cumulative change since FY2023) , GAAP net income of -$244.2M, operating cash flow of -$143.8M, and free cash flow of -$144.8M (+43.6% YoY). On the balance sheet, SANA closed FY2025 with $416.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $700.9M -$244.2M -$143.8M -$144.8M $416.9M —
FY2024 (FY) 2024-12-31 $763.6M -$266.8M -$223.2M -$256.6M $501.0M —
FY2023 (FY) 2023-12-31 $820.8M -$283.3M -$253.6M -$253.6M — —

3. SANA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Sana Biotechnology Inc. (NASDAQ: SANA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.40 (-6.61% 1D, market cap $769.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SANA ranks #671 in composite RQD confidence.

How does SANA compare to DNA and ATTO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SANA carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DNA (Ginkgo Bioworks Holdings Inc. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $721.3M) and ATTO (Attovia Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $693.4M). Among the 5-stock peer group, SANA leads on earnings multiple (N/A) while SANA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SANA?

Per SANA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770121), Sana Biotechnology Inc. generated $700.9M in revenue (-8.2% YoY), -$244.2M in net income, and -$144.8M in free cash flow against $416.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SANA trading relative to its 50-day, 200-day, and 52-week technical levels?

SANA last traded at $2.40 (-6.61% on volume of 2,596,135 shares), positioning the stock -19.73% below its 50-day simple moving average ($2.99) and -28.78% below its 200-day simple moving average ($3.37). Across its 52-week range of $2.22 to $5.49, SANA sits at the 5.5% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.10 to $2.70).

Direct Sub-Reports: SANA RQD Cockpit SANA 12M Forecast SANA Earnings & Move SANA Dividends & DRIP SANA Insiders & 13F SANA Whale Options SANA Profit Sankey SANA News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

SANA — Sana Biotechnology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sana Biotechnology Inc. (SANA) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.40 (-6.61% 1D, market capitalization $769.4M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.78%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sana Biotechnology Inc. (SANA) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. The company's products, customers, and revenue model are — The FY 2025, FY 2024, and FY 2023 financials report revenue of — in each period, . News headlines reference type 1 diabetes (T1D) treatment data, .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sana Biotechnology Inc. (SANA) reported $700.9M in annual revenue (up from $763.6M in FY2024, -8.2% YoY) and -$244.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($820.8M revenue, -$283.3M net income) through FY2025, SANA scaled operating cash flow to -$143.8M and free cash flow to -$144.8M, backed by $416.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.78% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.22 – $5.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), SANA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can SANA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $700.9M and free cash flow of -$144.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SANA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SANA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sana Biotechnology Inc. (SANA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SANA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SANA Bull vs. Bear Conversation Board — What's Your Call at $2.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SANA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SANA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $3.26 (+26.8%)
📌 Pinned Debate

Recent headlines reference promising early T1D treatment data, and the stock trades 3.42% higher on the day at $2.72 with a 52-week ran

Recent headlines reference promising early T1D treatment data, and the stock trades 3.42% higher on the day at $2.72 with a 52-week range of $2.22 - $5.49.. When you look under the hood at SANA, Fundamental Cash Engine is 9/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $5.49. My 12M target is $3.26.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 5/20 institutional whale-flow stock at $2.57 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.03 (-21.0%)
Spot @ $2.57

The company reported net losses of -$244.2M in FY 2025 with no revenue, an ROIC of -35%, and cash falling from $127.6M to $71.9M.

Fading this rally in SANA at $2.57. The company reported net losses of -$244.2M in FY 2025 with no revenue, an ROIC of -35%, and cash falling from $127.6M to $71.9M.. With a beta of 1.0 and the stock sitting at $2.57 (52-wk range $2.22–$5.49), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%